Archive for Urology News



Page 5«..4567..1020..»


Shoag joins UH Department of Urology – Cleveland Jewish News

Dr. Jonathan Shoag recently became a member of the University Hospitals Department of Urology team. Shoag, who specializes in bladder, kidney, prostate and urological cancers, has offices at both the UH Cleveland Medical Center in Cleveland and the UH Ahuja Medical Center in Beachwood, according to a news release

Read More..

In face of COVID-19 threat, more dialysis patients bring treatment home – FierceBiotech

NIPOMO, Calif.

Read More..

Nephrology And Urology Devices Market Incredible Possibilities, Growth Analysis and Forecast To 2026 |112233 – The Daily Chronicle

Overview Of Nephrology And Urology Devices Industry 2020-2025: This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

Read More..

PROCEPT BioRobotics Announces Medicare and Commercial Reimbursement Coverage for Aquablation Therapy for Enlarged Prostate – PRNewswire

REDWOOD CITY, Calif., Sept. 24, 2020 /PRNewswire/ --PROCEPTBioRobotics Corporation, a surgical robotics company developing intelligent solutions to transform the field of urology, today announced that National Government Services (NGS) is the first Medicare Administrative Contractor (MAC) to establish a final coverage policy for Aquablation therapy delivered by the AquaBeamRobotic System for the treatment of benign prostatic hyperplasia (BPH).

Read More..

Local Bride Appears on Magazine Cover – Effingham’s News and Sports Leader, 979XFM and KJ Country 102.3 – Effingham’s News Leader

Published on September 24 2020 1:39 pmLast Updated on September 24 2020 4:50 pmWritten by Greg Sapp A local bride has appeared on the cover of a magazine for professional photographers, and a local photographer is being recognized for the photo.

Read More..

Searchlight Pharma named to The Globe and Mail’s second-annual ranking of Canada’s Top Growing Companies – Canada NewsWire

MONTREAL, Sept. 25, 2020 /CNW Telbec/ -Searchlight Pharma is pleased to announce that it has been named to The Globe and Mail's Report on Business second-annual ranking of Canada's Top Growing Companies. Based on a three-year growth rate of 260% (2016-2019), Searchlight Pharma ranked No

Read More..

With Rucaparib Approval, Prostate Cancer Joins the Precision Oncology Era – Renal and Urology News

In an unusual move, the US Food & Drug Administration on May 15, 2020, granted accelerated approval to Clovis Oncology for the oral PARP inhibitor rucaparib as a treatment for metastatic castration-resistant prostate cancer (mCRPC), based on objective tumor and prostate-specific antigen (PSA) response rates from a single-arm phase 2 trial (TRITON2; ClinicalTrials.gov Identifier NCT02952534).1,2 The study included only 115 patients with germline or somatic BRCA-altered mCRPC and overall response rate (ORR) was evaluable in just 62 of those patients, who had measurable tumors.2 Full FDA approval will be contingent on demonstration of safety and efficacy in the ongoing multicenter, randomized, open-label phase 3 TRITON3 trial; findings are expected in the second half of 2021.3 The following week, on May 20, 2020, the FDA also announced approval of olaparib for mCRPC harboring deleterious germline or somatic mutations in any of 14 homologous recombination repair genes, including BRCA1 and BRCA2, based on improved radiographic response duration (rPFS) findings from the randomized phase 3 PROfound study (ClinicalTrials.gov Identifier: NCT02987543).4 The rucaparib approval was surprising but justified, according to Emmanuel Antonarakis, MD, professor of oncology and urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland. (Dr Antonarakis has received honoraria and consultancy payments from Clovis Oncology.) While the FDAs decision was surprising to me, and unprecedented in prostate cancer, it makes sense in retrospect given the strong rationale behind PARP inhibitors and the impressive objective response rate seen with rucaparib in prostate cancer patients with BRCA1/2 mutations, Dr Antonarakis told Cancer Therapy Advisor

Read More..

Urology Implants and Devices Market Size 2020 Top Manufacturers, Share, Opportunities and Forecast to 2026 – Crypto Daily

The Global Urology Implants And Devices Market is projected to grow considerably on account of increasing incidence of urology disorders.

Read More..

The global urinary catheters market size is projected to reach USD 2.6 billion by 2025 from USD 2.0 billion in 2020, at a CAGR of 5.5% – GlobeNewswire

New York, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Urinary Catheters Market by Product, Type, Application, Usage, End Users - Global Forecast to 2025" - https://www.reportlinker.com/p05974231/?utm_source=GNW The global urinary catheters market size is projected to reach USD 2.6 billion by 2025 from USD 2.0 billion in 2020, at a CAGR of 5.5% during the forecast period.

Read More..

Fewer than seven in 10 urological cancer patients treated within two months at Morecambe Bay hospitals trust – Lancaster Guardian

The Royal Lancaster Infirmary. Prostate Cancer UK said it is critical that men most at risk of their cancer progressing are prioritised for treatment across England while NHS services work to restore their normal service.

Read More..

Investigators ID Predictors of CKD Progression After Radical Nephrectomy – Renal and Urology News

Nephron hypertrophy and nephrosclerosis may be important determinants of chronic kidney disease (CKD) progression and death after radical nephrectomy (RN), according to new study findings. Using a precise approach, pathologists detailed microstructural features of kidney parenchyma (a large wedge not involved with tumor) obtained from 936 patients without a specific kidney disease (mean age 64 years; 92% White)

Read More..

Urology Implants and Devices Market Size 2020 Top Manufacturers, Share, Opportunities and Forecast to 2026 – The Daily Chronicle

The Global Urology Implants And Devices Market is projected to grow considerably on account of increasing incidence of urology disorders. Key insights into this development have been provided by Fortune Business Insights in its report, titled Urology Implants and Devices Market Size, Share and Global Trend By Product Type (Endoscopes, Lithotripsy Devices, Urodynamic Systems, Urostomy Bag, Endo Vision Systems & Peripheral Instruments, Urology Implants), By Disease (Kidney Disorders, Urology Cancers, Urinary Tract Disorders, Pelvic Organ Prolapse), By End User (Hospitals, Pharmacies, Ambulatory Surgery Centers (ASC)) and Geography Forecast till 2026

Read More..

MellingMedical Partners with Lions VisionGift Advancing Visual Health Options for Texas Veterans – PRNewswire

ALEXANDRIA, Va., Sept.

Read More..

Ibex Medical Analytics Wins UK Award to Accelerate Adoption of AI-Powered Cancer Detection in the NHS – PRNewswire

Ibex was selected among the first ever winners of the AI in Health and Care Award, sharing 50 million to enable a study of Ibex's AI technology across multiple NHS trusts TEL AVIV, Israel, Sept. 22, 2020 /PRNewswire/ --Ibex Medical Analytics, the pioneer in artificial intelligence (AI)-based cancer diagnostics, has won a share of a 50 million fund as part of the UK's AI in Health and Care Award for accelerating the rollout of healthcare projects with promising AI technologies across the NHS

Read More..

Health care firm welcomes new COO – Business Observer

FORT MYERS Jason Coe, a 25-year veteran of the health care industry, has been named chief operating officer of Florida Cancer Specialists & Research Institute (FCS) in Fort Myers.

Read More..

Where can you get tested for COVID-19 in the Midlands? – WLTX.com

DHEC has these locations available in South Carolina for the week of Sept.

Read More..

News in brief 09/21/2020 – The Recorder

Job fairs planned in Fonda, Rug CityKeymark Corporation and Kasson & Keller will be holding open air job fairs with same-day interviews.Participants will be able to visit a tent set up in the parking lot to fill out an application. Face masks must be worn at the job fairs.Job fairs will be held: Today, at Keymark Corporation, 1188 Cayadutta St., Fonda, from 10 a.m

Read More..

Musing: Doctors and dining – Marion Star

Brenda Donegan, Musing Published 8:50 a.m.

Read More..

SOC Induces Early Response Over Avelumab in Metastatic Urothelial Carcinoma – Cancer Network

Induction therapy with avelumab (Bavencio) prior to standard of care (SOC) gemcitabine/carboplatin failed to sustain clinically meaningful efficacy and is not an adequate strategy for the first-line treatment for patients with metastatic urothelial carcinoma (mUC), according to early data from a phase 2 trial presented at the 2020 ESMO Virtual Congress.1 The sequence of short-term checkpoint inhibition followed by combination of avelumab and gemcitabine/carboplatin followed by avelumab maintenance therapy seems to be a quite reasonable approach in this hard to treat treatment population, said invited discussant Kilian M. Gust, MD, head of uro-oncology in the Department of Urology at the Medical University of Vienna, in Austria, during a presentation at the meeting.

Read More..

‘We need a more healthy relationship with the penis’ says expert behind new owner’s ‘manual’ – iNews

Much as one doesnt become a professional football player by accident, so one doesnt find oneself a professional penis expert by mere chance. As a young man, Dr Piet Hoebeke had dreams of becoming a vet before ultimately deciding hed rather tend to the ailments of human beings

Read More..

EAU Issues Updated UTUC Guidelines – Renal and Urology News

The European Association of Urology (EAU) has updated its 2017 guidelines on upper tract urothelial carcinoma (UTUC) based on a review of the latest evidence. Here are some key recommendations from the guidelines, which were published in European Urology by Morgan Rouprt, MD, of Sorbonne University in Paris, France, and colleagues. Lynch syndrome and exposure to aristolochic acid or smoking all increase the risk for UTUC.

Read More..

AVEO Oncology Announces European Urology Publication of Final Overall Survival Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma -…

AVEO Oncology (Nasdaq: AVEO) today announced that final overall survival (OS) results from its Phase 3 TIVO-3 study were published in the journal European Urology. TIVO-3 is the Companys pivotal Phase 3 trial comparing tivozanib, AVEOs next-generation vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) drug candidate, to sorafenib in third and fourth line renal cell carcinoma (RCC). The article, titled "Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma," is available online first via this link

Read More..

Nephrology and Urology Devices Market to Witness Exponential Growth by 2020-2027 | Leading Players Nikkiso Co.Ltd., Fresenius Medical Care AG &…

Fort Collins, Colorado The report on the Nephrology and Urology Devices Market provides an in-depth assessment of the Nephrology and Urology Devices market including technological advancements, market drivers, challenges, current and emerging trends, opportunities, threats, risks, strategic developments, product advancements, and other key features.

Read More..

Choyce Peterson, Exclusive Listing Agent for 623 Newfield Avenue in Stamford, Successfully Leases Building to Hartford HealthCare Corporation – WFMZ…

NORWALK, Conn., Sept. 17, 2020 /PRNewswire/ --Choyce Peterson, Inc

Read More..

Darolutamide Prolongs Overall Survival in nmCRPC – Renal and Urology News

Darolutamide prolongs overall survival for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), according to a final analysis of the phase 3 Androgen Receptor Antagonizing Agent for Metastasis-Free Survival trial (ARAMIS; NCT02200614). An interim analysis conducted in 2019 confirmed longer metastasis-free survival. Overall survival at 3 years was 83% among darolutamide-treated patients compared with 77% among placebo-treated patients

Read More..